Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: Prospects for molecular diagnosis and risk prediction.

biopsy clinical research/ practice infection and infectious agents - viral: BK/ JC/ polyoma infectious disease kidney transplantation/ nephrology molecular biology: mRNA/ mRNA expression pathology/ histopathology rejection: T cell-mediated (TCMR)

Journal

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638

Informations de publication

Date de publication:
12 2020
Historique:
received: 19 01 2020
revised: 03 04 2020
accepted: 25 04 2020
pubmed: 7 5 2020
medline: 21 5 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

Novel tools are needed to improve diagnostic accuracy and risk prediction in BK virus nephropathy (BKVN). We assessed the utility of intragraft gene expression testing for these purposes. Eight hundred genes were measured in 110 archival samples, including a discovery cohort of native kidney BKVN (n = 5) vs pure T cell-mediated rejection (TCMR; n = 10). Five polyomavirus genes and seven immune-related genes (five associated with BKVN and two associated with TCMR) were significantly differentially expressed between these entities (FDR < 0.05). These three sets of genes were further evaluated in samples representing a spectrum of BK infection (n = 25), followed by a multicenter validation cohort of allograft BKVN (n = 60) vs TCMR (n = 10). Polyomavirus 5-gene set expression reliably distinguished BKVN from TCMR (validation cohort AUC = 0.992), but the immune gene sets demonstrated suboptimal diagnostic performance (AUC ≤ 0.720). Within the validation cohort, no significant differences in index biopsy gene expression were identified between BKVN patients demonstrating resolution (n = 35), persistent infection (n = 14) or de novo rejection (n = 11) 6 months following a standardized reduction in immunosuppression. These results suggest that, while intragraft polyomavirus gene expression may be useful as an ancillary diagnostic for BKVN, assessment for concurrent TCMR and prediction of clinical outcome may not be feasible with current molecular tools.

Identifiants

pubmed: 32372431
doi: 10.1111/ajt.15980
pii: S1600-6135(22)21629-3
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3486-3501

Informations de copyright

© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Références

Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79(10):1277-1286.
Hirsch HH, Randhawa P. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):179-188.
Nickeleit V, Singh HK, Randhawa P, et al. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol. 2018;29(2):680-693.
Hirsch HH, Randhawa PS. BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13528.
Adam B, Randhawa P, Chan S, et al. Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproducibility of polyomavirus immunohistochemistry in kidney allografts. Am J Transplant. 2014;14(9):2137-2147.
Nankivell BJ, Renthawa J, Sharma RN, Kable K, O'Connell PJ, Chapman JR. BK virus nephropathy: histological evolution by sequential pathology. Am J Transplant. 2017;17(8):2065-2077.
Drachenberg CB, Papadimitriou JC, Chaudhry MR, et al. Histological evolution of BK virus-associated nephropathy: importance of integrating clinical and pathological findings. Am J Transplant. 2017;17(8):2078-2091.
Nickeleit V, Mihatsch MJ. Polyomavirus allograft nephropathy and concurrent acute rejection: a diagnostic and therapeutic challenge. Am J Transplant. 2004;4(5):838-839.
Menter T, Mayr M, Schaub S, Mihatsch MJ, Hirsch HH, Hopfer H. Pathology of resolving polyomavirus-associated nephropathy. Am J Transplant. 2013;13(6):1474-1483.
Mengel M. BK virus nephropathy revisited. Am J Transplant. 2017;17(8):1972-1973.
Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol. 2016;12(9):534-548.
Halloran PF, Venner JM, Madill-Thomsen KS, et al. Review: the transcripts associated with organ allograft rejection. Am J Transplant. 2018;18(4):785-795.
Mannon RB, Hoffmann SC, Kampen RL, et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant. 2005;5(12):2883-2893.
Sigdel TK, Bestard O, Salomonis N, et al. Intragraft antiviral-specific gene expression as a distinctive transcriptional signature for studies in polyomavirus-associated nephropathy. Transplantation. 2016;100(10):2062-2070.
Pan L, Lyu Z, Adam B, et al. Polyomavirus BK nephropathy-associated transcriptomic signatures: a critical reevaluation. Transplant Direct. 2018;4(2):e339.
Schwarz A, Mengel M, Haller H, Niedermeyer J. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant. 2005;5(10):2582-2585.
Barber CE, Hewlett TJ, Geldenhuys L, Kiberd BA, Acott PD, Hatchette TF. BK virus nephropathy in a heart transplant recipient: case report and review of the literature. Transplant Infectious Dis. 2006;8(2):113-121.
Sharma SG, Nickeleit V, Herlitz LC, et al. BK polyoma virus nephropathy in the native kidney. Nephrol, Dialysis, Transplant. 2013;28(3):620-631.
Zeng Y, Magil A, Hussaini T, et al. First confirmed case of native polyomavirus BK nephropathy in a liver transplant recipient seven years post-transplant. Ann Hepatol. 2015;14(1):137-140.
Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.
Adam B, Afzali B, Dominy KM, et al. Multiplexed color-coded probe-based gene expression assessment for clinical molecular diagnostics in formalin-fixed paraffin-embedded human renal allograft tissue. Clin Transplant. 2016;30(3):295-305.
Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307.
Adam BA, Smith RN, Rosales IA, et al. Chronic antibody-mediated rejection in nonhuman primate renal allografts: validation of human histological and molecular phenotypes. Am J Transplant. 2017;17(11):2841-2850.
Dromparis P, Aboelnazar NS, Wagner S, et al. Ex vivo perfusion induces a time- and perfusate-dependent molecular repair response in explanted porcine lungs. Am J Transplant. 2019;19(4):1024-1036.
Reeve J, Sellarés J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant. 2013;13(3):645-655.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.
Zeng G, Huang Y, Huang Y, Lyu Z, Lesniak D, Randhawa P. Antigen-specificity of T cell infiltrates in biopsies with T cell-mediated rejection and BK polyomavirus viremia: analysis by next generation sequencing. Am J Transplant. 2016;16(11):3131-3138.
Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant. 2007;7(12):2712-2722.

Auteurs

Benjamin A Adam (BA)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Zeljko Kikic (Z)

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Siegfried Wagner (S)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Yassine Bouatou (Y)

Paris Translational Research Center for Organ Transplantation, Paris, France.

Juliette Gueguen (J)

Paris Translational Research Center for Organ Transplantation, Paris, France.

Fanny Drieux (F)

Department of Pathology, Necker Hospital, Paris, France.

Graeme Reid (G)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Katie Du (K)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Jan H Bräsen (JH)

Nephropathology Unit, Institute for Pathology, Hannover Medical School, Hannover, Germany.

Vivette D D'Agati (VD)

Department of Pathology, Columbia University Medical Center, New York, New York, USA.

Cinthia B Drachenberg (CB)

Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Evan A Farkash (EA)

Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.

Alton Brad Farris (A)

Department of Pathology, Emory University, Atlanta, Georgia, USA.

Laurette Geldenhuys (L)

Department of Pathology, Dalhousie University, Halifax, Canada.

Alexandre Loupy (A)

Paris Translational Research Center for Organ Transplantation, Paris, France.

Volker Nickeleit (V)

Division of Nephropathology, Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.

Marion Rabant (M)

Department of Pathology, Necker Hospital, Paris, France.

Parmjeet Randhawa (P)

Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Heinz Regele (H)

Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.

Michael Mengel (M)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH